Dupixent is not a JAK inhibitor. It is a biologic medication, specifically a monoclonal antibody that blocks a receptor involved in allergic inflammation. The two drug classes work in fundamentally different ways, but they treat some of the same conditions, which is why they’re often compared.
How Dupixent Actually Works
Dupixent (dupilumab) is classified as an interleukin-4 receptor alpha antagonist. It’s a lab-made antibody, a large protein injected under the skin, that attaches to a specific receptor on the outside of cells. By binding to this receptor, it blocks two chemical messengers called IL-4 and IL-13 from delivering their signals. These two messengers are key drivers of what doctors call Type 2 inflammation, the kind of immune overreaction behind conditions like eczema, asthma, and nasal polyps.
IL-4 primarily works in the immune system, promoting the allergic response at a cellular level. IL-13 is overproduced in inflamed skin and plays a larger role in tissue-level damage. Because both messengers share the same receptor subunit, Dupixent effectively shuts down both pathways with a single drug. This targeted approach is what makes it a biologic: it zeroes in on specific proteins rather than broadly suppressing the immune system.
How JAK Inhibitors Differ
JAK inhibitors work inside the cell rather than outside it. Where Dupixent is a large protein that blocks a receptor on the cell surface, JAK inhibitors are small molecules (taken as pills) that enter cells and block enzymes called Janus kinases. These enzymes act as relay switches, passing along signals from many different cytokines at once. Blocking them dampens multiple inflammatory pathways simultaneously.
That broader reach is a double-edged sword. JAK inhibitors can be very effective because they interrupt several inflammatory signals at once, but they also carry more serious safety concerns. The FDA requires its strongest warning label on JAK inhibitors like Rinvoq (upadacitinib), Xeljanz (tofacitinib), and Olumiant (baricitinib), citing increased risks of serious heart events, blood clots, certain cancers including lymphoma and lung cancer, and death compared to other anti-inflammatory treatments. In clinical trials, the cancer risk was roughly 48% higher with one JAK inhibitor compared to an older class of biologic. Dupixent does not carry these boxed warnings.
Interestingly, the signaling pathways aren’t completely separate. When IL-4 and IL-13 bind to their receptors, those receptors activate JAK1 and other Janus kinases inside the cell to pass the message along. So Dupixent blocks the signal before it reaches the JAKs, while JAK inhibitors block it after. They’re intervening at different points in overlapping pathways.
Why the Two Get Confused
Dupixent and JAK inhibitors are often prescribed for the same conditions, particularly moderate-to-severe atopic dermatitis (eczema). Two oral JAK inhibitors, abrocitinib (Cibinqo) and upadacitinib (Rinvoq), received FDA approval for eczema in recent years and are frequently discussed alongside Dupixent as alternatives. All three are considered when topical treatments aren’t enough.
The practical differences for patients are significant. Dupixent is a subcutaneous injection, typically given every two weeks. JAK inhibitors are daily pills. Some people prefer the convenience of a pill; others prefer the safety profile of the biologic. Your doctor will weigh your specific risk factors, disease severity, and preferences when recommending one over the other.
What Dupixent Is Approved to Treat
Dupixent has one of the broadest approval lists of any biologic, reflecting how many conditions involve IL-4 and IL-13 signaling. As of 2025, the FDA has approved it for:
- Atopic dermatitis in patients 6 months and older with moderate-to-severe disease
- Asthma with an eosinophilic phenotype or oral steroid dependence, ages 6 and up
- Chronic rhinosinusitis with nasal polyps in patients 12 and older
- Eosinophilic esophagitis in patients 1 year and older weighing at least 15 kg
- Prurigo nodularis in adults
- COPD with an eosinophilic phenotype in adults
- Chronic spontaneous urticaria in patients 12 and older who don’t respond to antihistamines
- Bullous pemphigoid in adults
JAK inhibitors overlap with Dupixent mainly in eczema and, to some extent, asthma. But the two drug classes are not interchangeable across all these conditions. Dupixent’s specificity for Type 2 inflammation makes it particularly well suited for allergic and eosinophilic diseases, while JAK inhibitors are also used in conditions like rheumatoid arthritis and psoriatic arthritis where different inflammatory pathways dominate.